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a b s t r a c t
By combining the total cell evolution curve and a two-compartmentmodel interactingwith
dynamic anti-cancer agents, the evolution of subpopulations has been analytically obtained
and investigated in this work.
© 2009 Elsevier Ltd. All rights reserved.
1. Introduction
The growth and control of tumors has long been the subject of much medical and scientific scrutiny. Physics and
mathematics can also be applied to analyze the evolution of tumor cells, as a fundamental step in understanding and
improving treatment. Cancerous tumors originate from the mutation of one or more cells which usually undergo rapid,
uncontrolled growth. Curve fitting has shown that the growth of an untreated tumor can be successfully described as
Gompertzian [4–7]. Different therapeutic strategies including surgery [8], chemotherapy [9,1,2,10,11], radiotherapy [12],
virotherapy [13–15], and even very recently radiovirotherapy [16,17], have been mathematically modeled by several
research groups. All of these attemptswork together to support the goal of understanding cancer andmaximizing the success
of treatment.
Monitoring the aging of a tumor can be done by tracking the total number of tumor cells, while also tracking two
subpopulations within it. Cells in the first subpopulation are active and known as proliferating cells, while cells in the
second group aremainly quiescent [18]. In this dynamic system, proliferating and quiescent subpopulations can convert into
each other; both subpopulations are affected by the natural death rate, and the proliferating subpopulation is also affected
by the proliferating rate. Two cell population dynamics can be expressed in a mathematical model framework in terms
of ordinary linear differential equations [19,20,18]. Recently, fitting the Gompertzian function [18] within the context of
two-compartment cell population dynamics, in the model presented by Kozusko and Bajzer, these authors predicted an
analytical solution for the evolution of two kinds of subpopulations within the tumor [3]. They lately modified their model
to include the presence of anti-mitotic drugs, when the drugs decrease the reproduction constant and increase the death
rate of the proliferating subpopulation. The drug amount is considered to be constant in their study [21].
Equipped with the Kozusko–Bajzer model, the principle aim of this work is to extend the two-compartment model
interacting with dynamic anti-mitotic drugs, which show a diffusion behavior over time after injection. The work is
organized as follows. Section 2 briefly reviews the combined Gompertzian growth with cell population dynamics presented
in theKozusko andBajzermodel. Section 3 extends thismodel to interactionwith a dynamic anti-mitotic drug. Exact analytic
expressions for the evolution of subpopulations during the interaction with drugs are presented. Section 4 investigates
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Fig. 1. Two-compartment model of cell population growth.
the evolution of the proliferating compartment through the simulation of different drug parameters. This section will be
followed with a conclusion and a discussion of the results.
2. The Kozusko–Bajzer model
The Kozusko–Bajzer model is a combined model of the Gompertzian function and the two-compartment model. The
Gompertzian function is a mathematical model of tumor growth [5,3]. This function is given in Eq. (1):
N1(t) = N01 exp
[
k+
k−
(1− exp(−k−t))
]
, (1)
where N1(0) = N01 and N1(t) stands for the total number of cells after time t during the growing phase. N01 represents
the initial cellularity. k+ represents a growth rate constant, while k− represents the retardation of growth. The two-
compartment model describes the evolution of the two compartments of a tumor [18]. This model consists of proliferating,
P1, and quiescent, Q1, cell compartments. The index of 1 accounts for the tumor during the growing phase. A schematic view
of the two-compartment model is shown in Fig. 1. In this view,µp andµq are natural cell decay rates for each compartment,
and β represents the reproduction rate of proliferating cells. In the model, the transition rate functions (ri(N1), ro(N1)) are
considered to be functions of the total number of cells. The evolution of each of these two compartments can be expressed
by the following ordinary differential equations:
dP1
dt
= [β − µp − ro(N1)] P1 + ri(N1)Q1, (2a)
dQ1
dt
= ro(N1)P1 −
[
ri(N1)+ µq
]
Q1, (2b)
where N1 = P1+Q1 and P1(0)+Q1(0) = 1. Kozusko and Bajzer combined the Gompertz and two-compartmentmodels [3].
The combined model introduces a net inter-compartmental transition rate and predicts the exact analytical solution for the
proliferating and quiescent subpopulations and their evolution over time. As calculated in their paper, the analytical solution
for subpopulations is expressed as below:
P1(t) = µq + k+ exp(−k−t)
β + µq + µp N1(t) = P0
µq + k+ exp(−k−t)
µq + k+ N1(t), (3)
and Q1 = N1 − P1. As can be seen above, the right hand side of the equation is expressed in terms of P0. This expression has
eliminated the parameters µq and β [3].
3. Extended Kozusko–Bajzer model interacting with dynamic anti-mitotic drugs
The effects of drugs on tumor growth have beenmathematically modeled from different perspectives [9,1,2,10,11]. They
may affect both quiescent and proliferating cell subpopulations or just proliferating cells in the form of cell-cycle specific
drugs [10,11]. In a recent work presented by Kozusko et al., ordinary differential equations for the two-compartment cell
population dynamics have been modified for anti-mitotic therapy. In this model, a drug decreases the production rate
constant and increases the death rate constant of proliferating cells, while the drug amount is constant over time [21].
During the course of therapy, the action of a drug can be modeled by adding a killing on–off term or, as a step function with
constant amplitude, to the kinetic ODEs of the system [11]. However, a more realistic drug term would include a decaying
behavior over time after the drug injection has stopped, which is the emphasis of this work [9,2].
This extended model includes the drug kill terms while the drug is actively decaying as a function of time. The response
functions for drug exposure can be mathematically structured as F(u) = ai(1 − exp(−mu)), where m is linked to
pharmacokinetics and is considered to be 1 in this primary study [9]. In this expression, 1− exp(−u) is the chemotherapy
fractional cell kill and u is the amount of the drug at the tumor site at the specific time. The coefficient of ai is the response
coefficient factor, which is different for P cells versusQ cells. The kinetics of the drug can be expressed as du/dt = v(t)−d·u,
where v(t) is the given dose and d is the per capita decay rate. This work concentrates on the phase when the drug is no
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Fig. 2. Two-compartment model interacting with dynamic anti-mitotic drugs.
longer being injected, v(t) = 0, and u has the exponentially decaying behavior of u(t) = u0 exp(−d · t) [9]. In this equation,
u(0) = u0 is the initial concentration of the drug. Tomodify the Kuzosko–Bajzermodel, these drug terms can be added to the
two-compartment model structure. The index of 2, in our notation, accounts for this interaction phase, where the total cell
population, N2, has a decaying behavior. The schematic view of the extended two-compartment model of cell populations
in the presence of chemotherapy is presented schematically in Fig. 2. The modified differential equations presenting the
kinetics of the system are
dP2
dt
= [β − µp − ro(N2)− ap(1− exp(−u))] P2 + ri(N2)Q2, (4a)
dQ2
dt
= ro(N2)P2 −
[
ri(N2)+ µq + aq(1− exp(−u))
]
Q2, (4b)
N2 = P2 + Q2. (4c)
Using Eqs. (4a) and (4b), we re-form Eq. (4c) into
dN2
dt
= [β − µp + µq + (aq − ap)(1− exp(−u))] P2 − [µq + aq(1− exp(−u))]N2, (5)
which leads to
P2(t) = dN2/dt +
[
µq + aq(1− exp(−u))
]
N2
β − µp + µq + (aq − ap)(1− exp(−u)) =
dN2/dt +
[
µq + aq(1− exp(−u))
]
N2
S + (aq − ap)(1− exp(−u)) . (6)
Here
S = −(aq − ap)(1− exp(−u0))+ N02P02
[
µq + aq(1− exp(−u0))
]+ dN02/dt
P02
.
The specification of Eq. (6) is at the boundary condition. At t = the starting point of the interacting phase, the size of
the proliferating cells is the same as the size of the proliferating cells at the end of the growing phase, phase 1. An explicit
analytical expression for the evolution of the proliferating subpopulation during the course of therapy is derived. Through
the following model simulation, the effects of the drugs on the size of proliferating cells is investigated.
4. Model simulation
To study the effects of drugs on the size of subpopulations, Eq. (6) is simulated in this section. To proceed with the
computer simulation, the total cell population, N2 is essential. The function of N2 can be estimated by a curve fitting
method. However, since in this work we have stressed on the drug behaviors in the evolution of the subpopulations a
simple function is considered for the N2. We have assumed that the treatment was successful and the total number of cells
drops over time during the course of therapy. An exponentially decaying behavior with a decay constant k is considered for
N2 = N02 exp(−kt). In this expression N20 = N1at−the−start−of−therapy.
Fig. 3 presents the behavior of the proliferating cells for a different drug decay factor, d. As can be expected, the more
stable drug with a smaller decay factor, d, better controls the fast growing size of P cells at the beginning of therapy.
Fig. 3a, k = 1.0, is a simulation for the case when the total cell population decays faster as compared to the Fig. 3b,
k = 0.8. The size of the P cells for k = 0.8 reaches a higher maximum value compared to the maximum value reached
by k = 1.0. Also, the time taken for the P cells to reach the maximum in k = 0.8 is longer than it is for k = 1.0. This is
illustrated in Fig. 3c.
For the next step, Fig. 4, we considered that a dynamic drug kills two kinds of subpopulations with different response
rates, ai. We first assumed that the responses to the drugs are the same for both P cells and Q cells. Then we considered
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Fig. 3. The ratio of cell proliferating in the interaction phase vs. time. The total cell population decay factor is changing, in A with (k = 1), and in B with
(k = 0.8). In this simulation aq = ap = 0.9, µ = 0.2, u0 = 1. The growing phase in this simulation is in the range 0–40 while the interaction phase is
between 40 and 41.5. The growth follows the Gompertzian function with k+1 = 2.76 and k−1 = 0.134. N01 = 1 and N02 = N1(40). P1(40)which follows
Eq. (3) is equal to P02 . The values of parameters are adapted from [1–3].
Fig. 4. The ratio of cell proliferating in the interaction phase vs. time. The total cell population decay factor is k = 1 and the drug decay factor is d = 1.5.
In this simulation ap = 0.9, µ = 0.2, u0 = 1, k+1 = 2.76 and k−1 = 0.134, and aq is changing.
that the drug killed the Q cells with a smaller rate. In the end, we considered that the drug is cell-cycle specific when it kills
only the P cells and has no effect on the Q cells. As illustrated in the simulation, the best response is related to the cell-cycle
drugs which show smaller proliferating cells. As noted by Kuzosko et al., as the killing rate for the quiescent cell population
increases, the size of proliferating cells increases as well in order to maintain the total cell population growth.
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In this work, the ordinary differential equations for the kinetics of cancerous subpopulations are modified by adding
extra killing drug terms to the two-compartment model. The drug has a decaying factor. We showed that the drug decay
factor has an important role as regards the size of P cells at the beginning of therapy. Also, the drug response factor has an
important role in controlling the size of subpopulations. The cell specific drugs are more effective in controlling the size of
P cells.
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